What is an oral SERD? How giredestrant, camizestrant, imlunestrant and elacestrant work in ESR1 mutated breast cancer, with FDA approvals compared in one table.
Last updated: November 17, 2026
An oral SERD is a pill that binds the estrogen receptor and triggers its breakdown. With Wilserdly (giredestrant) approved on November 16, 2026, FDA notices show five oral estrogen receptor degraders cleared for ESR1 mutated, ER positive, HER2 negative advanced breast cancer, each in a different setting.
Scope: how oral SERDs work, why ESR1 mutations matter, how the five FDA approvals differ, the testing that decides eligibility, and the decisions still ahead. This is a guide for industry readers, not treatment advice.
What is an oral SERD?
A selective estrogen receptor degrader, or SERD, is a drug that attaches to the estrogen receptor and marks it for destruction, so the cancer cell loses the signal it uses to grow. “Oral” is the point: the first SERD, fulvestrant, is an intramuscular injection, while the new generation is taken as a daily tablet.
That difference is practical as well as pharmacological. A daily pill can be combined with other oral drugs, such as CDK4/6 inhibitors or everolimus, into regimens patients take at home. Genentech’s release for Wilserdly leans on exactly that point, describing it as part of an “all oral regimen” with everolimus.
Why do ESR1 mutations matter in breast cancer?
ESR1 is the gene that encodes estrogen receptor alpha. Certain mutations in it leave the receptor switched on even when estrogen is low, which is how tumors escape aromatase inhibitors, the drugs that work by cutting estrogen production. Genentech says up to 40% of patients with hormone receptor positive metastatic breast cancer develop ESR1 mutations.
Because a SERD removes the receptor itself rather than starving it of estrogen, it can still work against a mutated, always on receptor. That is why every oral degrader approval covered here is restricted to tumors with a detected ESR1 mutation, and why each one comes with a test.
Which oral SERDs has the FDA approved?
FDA approval notices show four oral SERDs for ESR1 mutated advanced breast cancer: elacestrant in January 2023, imlunestrant in September 2025, camizestrant in September 2026 and giredestrant in November 2026. A fifth oral drug, vepdegestrant, approved in May 2026, also destroys the estrogen receptor but works differently; the FDA calls it a heterobifunctional protein degrader. Each approval covers a different line of therapy or partner drug, so they are not interchangeable.
| Drug (brand, sponsor) | FDA approval | Regimen in the label | Pivotal trial | ESR1 mutated patients | Median PFS, drug vs control | Hazard ratio (95% CI) | Test named by FDA or sponsor |
|---|---|---|---|---|---|---|---|
| Elacestrant (Orserdu, Stemline Therapeutics) | Jan 27, 2023 | Single agent; trial control was fulvestrant or an aromatase inhibitor | EMERALD (NCT03778931), 478 enrolled | 228 | 3.8 vs 1.9 months | 0.55 (0.39 to 0.77) | Guardant360 CDx |
| Imlunestrant (Inluriyo, Eli Lilly) | Sept 25, 2025 | Single agent after at least one line of endocrine therapy | EMBER-3 (NCT04975308), 874 enrolled | 256 | 5.5 vs 3.8 months | 0.62 (0.46 to 0.82) | Not named in Lilly’s release |
| Vepdegestrant (Veppanu, Arvinas); a protein degrader, not a classic SERD | May 1, 2026 | After at least one line of endocrine therapy; trial control was fulvestrant | VERITAC-2 (NCT05654623), 624 enrolled | 270 | 5 vs 2.1 months | 0.57 (0.42 to 0.77) | Guardant360 CDx |
| Camizestrant (Etcamah, AstraZeneca) | Sept 4, 2026 (accelerated) | With a CDK4/6 inhibitor, switching when an ESR1 mutation appears during aromatase inhibitor plus CDK4/6 therapy | SERENA-6 (NCT04964934) | 315 randomized | 16 vs 9.2 months | 0.44 (0.31 to 0.60) | Guardant360 CDx |
| Giredestrant (Wilserdly, Genentech) | Nov 16, 2026 | With everolimus, after endocrine therapy failure | evERA (NCT05306340), 373 enrolled | 207 | 10 vs 5.5 months | 0.38 (0.27 to 0.54) | FoundationOne Liquid CDx |
Rows are in order of approval. Sources: FDA approval notices for elacestrant, vepdegestrant, camizestrant and giredestrant; Lilly’s September 25, 2025 release for imlunestrant. In SERENA-6, every randomized patient had an ESR1 mutation detected in circulating tumor DNA. The FDA’s oncology approvals list also shows a separate September 18, 2026 approval of imlunestrant in combination with abemaciclib for ESR1 mutated disease; we have not reviewed that notice’s trial data, so it is not in the table.
Do not rank these drugs by the PFS column. The trials enrolled different patients at different points in treatment, used different control arms and partner drugs, and in SERENA-6 the comparison was a switch strategy, not a later line of therapy. The table describes each label; it is not a head to head comparison.
How is giredestrant different from the earlier oral SERDs?
Giredestrant is the first oral SERD the FDA has approved in combination with everolimus, an mTOR inhibitor already used in this setting. The FDA notice describes evERA as an open label trial that randomized 373 patients to giredestrant 30 mg daily or physician’s choice of exemestane, fulvestrant or tamoxifen, all with everolimus 10 mg.
In the 207 patients with ESR1 mutations, median progression free survival was 10 months with giredestrant plus everolimus versus 5.5 months in the control arm (hazard ratio 0.38). Overall response rates were 27% and 14%, and overall survival was immature. The FDA approved the application four weeks ahead of its goal date, reviewed it under Project Orbis with Health Canada and Israel’s Ministry of Health, and authorized FoundationOne Liquid CDx as the companion test. Genentech says the drug should be available in the US in the coming weeks.
How is camizestrant different?
Camizestrant is approved for a strategy, not just a line of therapy: switching the endocrine partner as soon as a blood test detects an ESR1 mutation, before the cancer visibly progresses. Patients stay on their CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) and swap the aromatase inhibitor for camizestrant.
It is also the only one of the five with accelerated approval. The FDA notice says continued approval may depend on a confirmatory trial, that the application received standard review, and that it carried breakthrough therapy designation. That makes it a live example of the confirmatory rules we explain in our accelerated approval guide.
How is imlunestrant different?
Imlunestrant was approved as a single agent for patients whose disease progressed after at least one line of endocrine therapy. Lilly’s release gives a dose of 400 mg once daily, taken as two 200 mg tablets. In the 256 ESR1 mutated patients in EMBER-3, median progression free survival was 5.5 months versus 3.8 months on fulvestrant or exemestane.
The FDA’s approvals list now also shows imlunestrant with abemaciclib, approved September 18, 2026, which gives Lilly both a monotherapy and a CDK4/6 combination label.
Is vepdegestrant a SERD?
Not in the classic sense. The FDA describes vepdegestrant as a heterobifunctional protein degrader, a class of molecule designed to tether its target to the cell’s own protein disposal machinery rather than simply destabilize it. The goal, less estrogen receptor, is the same. The FDA approved it on May 1, 2026, one month ahead of its goal date, for ESR1 mutated disease that progressed after at least one line of endocrine therapy. In VERITAC-2’s 270 ESR1 mutated patients, median progression free survival was 5 months versus 2.1 months on fulvestrant, and the FDA lists QTc interval prolongation among its warnings.
Where does elacestrant fit?
Elacestrant was the first oral SERD the FDA approved, in January 2023, and it set the template: an ESR1 restricted label and a blood based companion test. In EMERALD’s 228 ESR1 mutated patients, median progression free survival was 3.8 months versus 1.9 months on fulvestrant or an aromatase inhibitor. The FDA notice lists a dose of 345 mg once daily with food and Guardant360 CDx as the companion diagnostic.
How are patients tested for ESR1 mutations?
All five labels depend on finding an ESR1 mutation, and the tests named so far are liquid biopsies that read tumor DNA in the blood. The FDA named Guardant360 CDx for elacestrant, vepdegestrant and camizestrant and FoundationOne Liquid CDx for giredestrant.
Testing timing now matters as much as the test. ESR1 mutations usually emerge during treatment, so a sample taken at diagnosis may be negative. Camizestrant’s label goes furthest, requiring detection during aromatase inhibitor plus CDK4/6 therapy, which implies repeat monitoring rather than a one time test. For diagnostics companies that is a recurring testing market; for health systems, it is a new line in the care pathway.
What decision comes next for oral SERDs?
The next decision is giredestrant in early breast cancer. Genentech says the FDA accepted a separate application based on the lidERA trial (NCT04961996) under priority review, with a PDUFA date of November 30, 2026. Genentech says an approval would make it the first new adjuvant endocrine therapy in over 20 years. Moving an oral SERD from metastatic disease into the curative setting would open a far larger and longer treated population than any metastatic label.
Our framework: how to read the next oral SERD approval
- Setting: which line of therapy, and is it a switch on mutation detection or a switch on progression?
- Partner drug: single agent, CDK4/6 inhibitor or everolimus? The partner shapes toxicity and cost.
- Control arm: fulvestrant, an aromatase inhibitor, physician’s choice, or placebo with continued therapy? A weak control flatters the hazard ratio.
- Population: is the label limited to ESR1 mutated tumors, and what happened in patients without the mutation?
- Test: which companion diagnostic, and does the label require testing at a specific time?
- Approval type: regular or accelerated, and what confirmatory trial is required?
- Endpoint maturity: is overall survival mature, or still pending?
What to watch next
- The FDA decision on giredestrant in adjuvant early breast cancer, with a PDUFA date of November 30, 2026, per Genentech. Remember that the FDA often acts early.
- US launch timing and pricing for Wilserdly, which Genentech says will be available in the coming weeks.
- Confirmatory evidence for camizestrant’s accelerated approval.
- Overall survival updates from evERA, SERENA-6, EMBER-3 and VERITAC-2.
- Guideline updates on when and how often to test for ESR1 mutations.
FAQ
What does SERD stand for?
Selective estrogen receptor degrader: a drug that binds the estrogen receptor and causes the cell to break it down.
How many oral SERDs are FDA approved?
FDA notices we reviewed show four as of November 17, 2026: elacestrant (Orserdu), imlunestrant (Inluriyo), camizestrant (Etcamah) and giredestrant (Wilserdly), plus vepdegestrant (Veppanu), an oral protein degrader with the same target. All are for ESR1 mutated, ER positive, HER2 negative advanced breast cancer.
When was giredestrant approved?
The FDA approved giredestrant, sold as Wilserdly, on November 16, 2026, in combination with everolimus.
Is giredestrant approved on its own?
No. The current label is only in combination with everolimus.
Which oral SERD has accelerated approval?
Camizestrant (Etcamah), approved September 4, 2026, in combination with a CDK4/6 inhibitor. The FDA says continued approval may depend on a confirmatory trial.
Is fulvestrant an oral SERD?
No. Fulvestrant is a SERD given by intramuscular injection. It served as a control arm comparator in several oral SERD trials.
What test is used to find ESR1 mutations?
The FDA named Guardant360 CDx for elacestrant, vepdegestrant and camizestrant, and FoundationOne Liquid CDx for giredestrant. Both analyze tumor DNA from a blood sample.
How common are ESR1 mutations?
Genentech says up to 40% of patients with hormone receptor positive metastatic breast cancer develop ESR1 mutations.
Can the oral SERD trials be compared directly?
No. The trials differ in patient population, line of therapy, partner drug and control arm, so their progression free survival results are not head to head comparisons.
Could oral SERDs be used in early breast cancer?
Genentech has a pending FDA application for giredestrant in early breast cancer based on the lidERA trial, with a PDUFA date of November 30, 2026.
Sources
Primary
- FDA, “FDA approves giredestrant in combination with everolimus for ER positive, HER2 negative, ESR1 mutated locally advanced or metastatic breast cancer,” November 16, 2026.
- Genentech, “FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next Generation Oral SERD, for ER Positive, ESR1 Mutated Advanced Breast Cancer,” November 16, 2026 (gene.com).
- FDA, “FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1 mutated, HR positive, HER2 negative breast cancer,” September 4, 2026.
- FDA, “FDA approves vepdegestrant for ER positive, HER2 negative, ESR1 mutated advanced or metastatic breast cancer,” May 1, 2026.
- Eli Lilly, “U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2 negative, ESR1 mutated advanced or metastatic breast cancer,” September 25, 2025 (investor.lilly.com).
- FDA, “FDA approves elacestrant for ER positive, HER2 negative, ESR1 mutated advanced or metastatic breast cancer,” January 27, 2023.
- FDA, Oncology (Cancer)/Hematologic Malignancies Approval Notifications list, accessed November 17, 2026 (imlunestrant plus abemaciclib entry, September 18, 2026).
Related coverage
- Our coverage of the FDA’s Etcamah approval on a ctDNA resistance signal
- Etcamah’s first line trial miss, eight days after approval
- FDA accelerated approval: confirmatory trial rules explained
- What is Project Orbis? How FDA shares cancer drug reviews
- PDUFA date explained: goal dates, extensions and FDA decisions
- BioMed Nexus company directory
Get the daily briefing that connects these stories: subscribe to BioMed Nexus.


